Atypical Chronic Lymphocytic Leukemia—The Current Status
Cancers · 05.09.2023 · 15 (18) · 4427
DOI: 10.3390/cancers15184427 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 05.09.2023. Verfasst von Tadeusz Robak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Medical University of Lodz, 90-647 Lodz, Poland. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lodz, Poland.
Abstract (Originalsprache)
A diagnosis of typical chronic lymphocytic leukemia (CLL) requires the presence of ≥5000 clonal B-lymphocytes/μL, the coexistence of CD19, CD20, CD5, and CD23, the restriction of light chain immunoglobulin, and the lack of expression of antigens CD22 and CD79b. Atypical CLL (aCLL) can be distinguished from typical CLL morphologically and immunophenotypically. Morphologically atypical CLL cells have been defined mainly as large, atypical forms, prolymphocytes, or cleaved cells. However, current aCLL diagnostics rely more on immunophenotypic characteristics rather than atypical morphology. Immunophenotypically, atypical CLL differs from classic CLL in the lack of expression of one or fewer surface antigens, most commonly CD5 and CD23, and the patient does not meet the criteria for a diagnosis of any other B-cell lymphoid malignancy. Morphologically atypical CLL has more aggressive clinical behavior and worse prognosis than classic CLL. Patients with aCLL are more likely to display markers associated with poor prognosis, including trisomy 12, unmutated IGVH, and CD38 expression, compared with classic CLL. However, no standard or commonly accepted criteria exist for differentiating aCLL from classic CLL and the clinical significance of aCLL is still under debate. This review summarizes the current state of knowledge on the morphological, immunophenotypic, and genetic abnormalities of aCLL.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Medical University of Lodz, 90-647 Lodz, Poland.
- Department of General Hematology, Copernicus Memorial Hospital, 93-513 Lodz, Poland.
- Department of Hematooncology, Copernicus Memorial Hospital, 93-513 Lodz, Poland.
ORCID-Profile: Tadeusz Robak, Barbara Cebula-Obrzut, Marta Urbaniak, Paweł Robak
Förderung
- Medical University of Lodz, Poland
Zitieren
APA
Robak, T., Krawczyńska, A., Cebula-Obrzut, B., Urbaniak, M., Iskierka-Jażdżewska, E., & Robak, P. (2023). Atypical Chronic Lymphocytic Leukemia—The Current Status. Cancers, 15(18), 4427. https://doi.org/10.3390/cancers15184427
Vancouver
Robak T, Krawczyńska A, Cebula-Obrzut B, Urbaniak M, Iskierka-Jażdżewska E, Robak P. Atypical Chronic Lymphocytic Leukemia—The Current Status. Cancers. 2023;15(18):4427. doi:10.3390/cancers15184427
BibTeX
@article{Robak2023,
author = {Robak, Tadeusz and Krawczyńska, Anna and Cebula-Obrzut, Barbara and Urbaniak, Marta and Iskierka-Jażdżewska, Elżbieta and Robak, Paweł},
title = {Atypical Chronic Lymphocytic Leukemia—The Current Status},
journal = {Cancers},
year = {2023},
volume = {15},
number = {18},
pages = {4427},
doi = {10.3390/cancers15184427}
}
EUVIMED